REFRACTORY AML
Clinical trials for REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY AML trials appear
Sign up with your email to follow new studies for REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Immune cell 'boost' aims to clear leukemia before transplant
Disease control Recruiting nowThis study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially grown natural killer cells from a donor to attack the leukemia, followed by a stem cell t…
Matched conditions: REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 26, 2026 06:23 UTC
-
Engineered immune cells take on tough leukemia in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called CLL-1 CAR-NK cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to better recognize and attack leukemia cells. Th…
Matched conditions: REFRACTORY AML
Phase: PHASE1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated May 26, 2026 06:22 UTC
-
New combo therapy targets tough leukemia gene mutations
Disease control Recruiting nowThis early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…
Matched conditions: REFRACTORY AML
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC